Novacyt S.A.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| NCYT.L | TRIB | QTI | VNRX | ALERS.PA | BMRA | |
|---|---|---|---|---|---|---|
| Market cap | 28.32M | 5.94M | 32.93M | 5.23M | 253.72M | 7.73M |
| P/E (TTM) | — | — | — | — | 36.0 | — |
| Forward P/E | -5.6 | -7.1 | -15.0 | -0.2 | 22.3 | 4.3 |
| Price/book | 1.5 | -0.1 | 13.8 | -0.1 | 1.3 | 2.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −4.84% | −76.14% | −63.65% | −98.07% | +3.49% | −43.24% |
| Today | −0.64% | −2.81% | −4.46% | +2.96% | 0.00% | 0.00% |
The closest companies by business and industry (Medical Devices). Prices may be delayed up to 15 min.
Latest news
All NCYT.L news ›Novacyt's strikes Illumina deal; Beeks' Thailand deal
The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: ---------- Novacyt SA - biotechnology group focused on clinical... Biotechnology & Medical Research…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
tradingview.com3
-
marketscreener.com1
-
seekingalpha.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 5 articles, not a forecast.